After he was elected, pharmaceutical stocks surged as investors concluded the threat of action on drug pricing had lessened. Trump has said he wants to repeal Obamacare, but hasn’t addressed the industry’s drug pricing problem that has largely dominated public discussion of pharmaceuticals in the past year.
Get the full story at our sister site, Drug Delivery Business News.
The post Pharma execs assess landscape under President Trump appeared first on MassDevice.
from MassDevice http://ift.tt/2g1Pw2w
Cap comentari:
Publica un comentari a l'entrada